Formosa Pharmaceuticals Partner Applied for Drug Review to Australian Drug Authority
MT Newswires Live
1 hour ago
Formosa Pharmaceuticals (TPE:6838) said its authorized partner, Arrotex Pharmaceuticals, has applied to the Therapeutic Goods Administration (TGA) of Australia for the drug inspection registration and review of the drug APP13007, according to a Friday filing to the Taiwan stock exchange.
The company's shares were down nearly 1% in Monday's trade.
The drug is intended for the treatment of inflammation and pain after eye surgery.
Arrotex Pharmaceuticals will bear all the costs associated with the application for drug inspection and registration.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.